BiotechTube
CHO-plus

CHO-plus

Cambridge, United States· Est.
cho-plus.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2014, CHO Plus addresses capacity constraints and high costs in biopharmaceutical manufacturing through proprietary cell line engineering. The company's technology platform creates GMP-compliant CHO and HEK-293 cell lines with dramatically enhanced productivity for monoclonal antibodies and AAV vectors. CHO Plus operates as a technology licensor, planning to generate revenue through royalties from biopharma partners using their engineered cell lines in commercial manufacturing processes.

Biomanufacturing TechnologyCell Line Development

Technology Platform

Patented genetic engineering technologies for creating highly productive mammalian cell lines (CHO and HEK-293) with up to 10-fold increases in protein production and over 15-fold improvements in AAV vector yields, coupled with screening technology that identifies high-producing clones more efficiently.

Opportunities

The severe capacity constraints in biomanufacturing, particularly for gene therapy viral vectors, create significant demand for productivity-enhancing technologies.
CHO Plus can enable existing facilities to increase output 5-10x without capital investment, while the shift toward more complex biologics and cell/gene therapies drives need for improved manufacturing efficiency.

Risk Factors

Key risks include regulatory acceptance of engineered cell lines, scale-up challenges from lab to commercial production, adoption resistance from risk-averse manufacturers with validated processes, and competition from established CDMOs with integrated platforms.
Intellectual property challenges in the crowded cell engineering space also present risks.

Competitive Landscape

CHO Plus competes with established CDMOs like Lonza and WuXi Biologics, as well as cell line developers like Selexis and ATUM. Their differentiation includes demonstrated 10x productivity improvements (vs. typical 2-5x for competitors), focus on both protein and viral vector production, and technology designed as drop-in replacements for existing manufacturing processes.

More companies in Biologics / Biosimilars →More companies in United States →